QIAGEN acquisition of NeuMoDx Molecular, Inc.
Acquisition17/09/2020
QIAGEN announced completed acquisition of the remaining [figure hidden] of NeuMoDx Molecular, Inc. on September 17, 2020 after US regulatory clearance. QIAGEN previously held [figure hidden] and had distributed its molecular-testing platforms outside the United States. The historical acquisition is distinct from later discontinuation of the NeuMoDx product line.
Type
Acquisition
Announced
17/09/2020
Amount
Financial data requires access
Reported parties
QIAGEN N.V.; NeuMoDx Molecular, Inc.